Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of SP-2577 (Seclidemstat) in Combination With Azacitidine for Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Next Previous
Trial Profile

Phase I/II Study of SP-2577 (Seclidemstat) in Combination With Azacitidine for Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Seclidemstat (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Feb 2025 According to a Salarius Pharmaceuticals media release, the company announced that patient enrollment will resume in this investigator-initiated Phase 1/2 clinical trial.
  • 13 Jan 2025 According to a Salarius Pharmaceuticals media release, company signed a definitive agreement under which Decoy Therapeutics will merge with Salarius Pharmaceuticals, and this intends to incorporate SP-3164 into a highly targeted peptide-based proteolysis targeting chimeras (PROTACS) drug candidate and support Phase 1/2 clinical trial at MD Anderson Cancer Center (MDACC) for seclidemstat.
  • 17 Jun 2024 Results(as of February 2024, n=14) assessing safety and efficacy presented in a Salarius Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top